This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Stocks · News reference
Synchrony Financial To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securities raise price targets. See analyst ratings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AbbVie Exec Says Plans To Start Enrolling Apogee's Zumilokibart This Year, Targets Launch In Early 2030; Says Will Present Late-stage Data For Blood Cancer Drug Etentamig At International Myeloma Society Meeting Later In September
https://event.webcasts.com/starthere.jsp?ei=1773801&tp_key=756e5e03ad&tp_special=8
AbbVie Exec Says Apogee Fits 'Very Nicely' With Its Business Development Approach; Says Existing Portfolio Provides 'Clear Line Of Sight' To Very Strong Growth Well Into Next Decade
- conference call
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Ken Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.
AGNC Investment To Be Added To S&P MidCap 400 Index, Effective September 21
AGNC Investment Corp. (NASDAQ:AGNC) ("AGNC" or the "Company") announced today that it will be added to the S&P MidCap 400 Index, effective prior to the open of trading on Monday, September 21, 2026.
If Zero Rates Are Gone for Good, What Is a Checking Account Worth to a Bank?
As interest rates rise, checking accounts become increasingly valuable to banks like Bank of America because they represent the lowest-cost source of capital available. Unlike mortgage REITs that are subject to market rates, banks have control over deposit rates and can maintain profitable spreads between borrowing and lending costs. The stickiness of customer relationships and switching costs further enhance the value of checking accounts in a higher-rate environment.